Immunotherapeutic Regulatory CD8 T cells in Autoimmune Demyelinating Disease
自身免疫性脱髓鞘疾病中的免疫治疗调节性 CD8 T 细胞
基本信息
- 批准号:9483533
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-01 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive ImmunotherapyAdoptive TransferAffectAnimal ModelAnti-inflammatoryAntigenic SpecificityAntigensAreaAutoantigensAutoimmune DiseasesAutoimmune ProcessCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCellsCharacteristicsChronicCountryDataDemyelinating DiseasesDemyelinationsDendritic CellsDevelopmentDiseaseExhibitsExperimental Autoimmune EncephalomyelitisExperimental ModelsGoalsHistologyHumanITGAX geneImmuneImmunizationImmunologicsImmunologyImmunotherapeutic agentImmunotherapyIn VitroInbred C3H MiceInflammatoryInterferon Type IIInterventionIntuitionMHC Class I GenesMediatingModelingMolecularMorbidity - disease rateMultiple SclerosisMultiple Sclerosis LesionsMusMyelinNeuraxisOrganPathogenesisPathogenicityPathologyPeripheralPharmaceutical PreparationsPhenotypePlayPopulationProcessRegulationRegulatory T-LymphocyteRelapseReportingRoleSJL MouseSiteT cell responseT-LymphocyteTherapeuticTherapeutic EffectTransgenic OrganismsVeteransWorkarmautoreactive T cellautoreactivitybasecentral nervous system demyelinating disordercopolymer 1cytotoxicexperimental studyimmunopathologyimmunoregulationin vivoinnovationinsightmouse modelneuroinflammationnovelperforinresponsetraffickingtreatment strategy
项目摘要
Multiple sclerosis (MS) is an inflammatory, demyelinating disorder of the central nervous system (CNS). A
great deal of our understanding about the immunologic processes that underlie MS derives from studies in its
autoimmune animal model, experimental autoimmune encephalomyelitis (EAE). However, the vast majority of
studies in EAE and MS have focused on evaluating and targeting CD4+ T cell responses, with the general
assumption that these diseases are predominantly Th1/Th17-mediated and Th2/Treg-modulated. Recent
reports from others and us indicate that CD8+ T cells play a role in the pathogenesis as well as regulation of
autoimmune demyelination. Our recent studies in MS and EAE have provided evidence for a novel and
unexpected disease suppressive role for CNS-specific CD8+ T cells and also demonstrated the
requirement of CD8+ T cells in mediating effects of glatiramer acetate (GA) immunotherapy. Based on
our data, we hypothesize that a subset of autoantigen-specific or GA-induced CD8 T cells form an
important arm of immune regulation during autoimmune demyelinating disease. We propose that this
process can be harnessed for the development of an effective immunotherapeutic strategy. The
experiments proposed in this application will utilize EAE models to address the fundamental cellular and
molecular mechanisms of immune modulation by intrinsic and therapeutic CD8 T cells. In addition, the most
potent immune suppressive subset of these populations will be defined with the goal of developing a novel
adoptive immunotherapeutic approach. We believe that the proposed experiments will provide greater
fundamental insights into CD8 T cell-mediated immune regulation and pave the way for newer intervention
strategies for this and other immune-mediated diseases.
多发性硬化(MS)是中枢神经系统(CNS)的炎性脱髓鞘疾病。一
我们对MS基础免疫过程的大量理解来自于其
实验性自身免疫性脑脊髓炎(EAE)。但绝大多数
EAE和MS的研究重点是评估和靶向CD 4 + T细胞反应,总体而言,
假设这些疾病主要是Th 1/Th 17介导的和Th 2/Treg调节的。最近
来自其他人和我们的报告表明,CD 8 + T细胞在发病机制以及调节
自身免疫性脱髓鞘我们最近在MS和EAE中的研究为一种新的,
CNS特异性CD 8 + T细胞的意想不到的疾病抑制作用,也证明了
在介导醋酸格拉替雷(GA)免疫疗法的作用中需要CD 8 + T细胞。基于
根据我们的数据,我们假设一个自身抗原特异性或GA诱导的CD 8 T细胞亚群形成了一个特异性的T细胞亚群。
在自身免疫性脱髓鞘疾病期间免疫调节重要手臂。我们建议,
可以利用这一过程来制定有效的免疫战略。的
本申请中提出的实验将利用EAE模型来解决基本的细胞和
内在和治疗性CD 8 T细胞免疫调节的分子机制。此外,最
这些人群的有效免疫抑制亚群将被定义,目的是开发一种新的免疫抑制剂。
过继免疫方法我们认为,拟议的实验将提供更大的
对CD 8 T细胞介导的免疫调节的基本见解并为新的干预措施铺平道路
治疗这种疾病和其他免疫介导疾病的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NITIN J KARANDIKAR其他文献
NITIN J KARANDIKAR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NITIN J KARANDIKAR', 18)}}的其他基金
Effector-Regulator Immune Interactions During Autoimmune Demyelinating Disease
自身免疫性脱髓鞘疾病期间效应器-调节器免疫相互作用
- 批准号:
10595509 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Effector-Regulator Immune Interactions During Autoimmune Demyelinating Disease
自身免疫性脱髓鞘疾病期间效应器-调节器免疫相互作用
- 批准号:
10359998 - 财政年份:2022
- 资助金额:
-- - 项目类别:
ShEEP Request for Cytek Aurora Spectral Flow Cytometer
ShEEP 请求 Cytek Aurora 光谱流式细胞仪
- 批准号:
9905780 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Immunotherapeutic Regulatory CD8 T cells in Autoimmune Demyelinating Disease
自身免疫性脱髓鞘疾病中的免疫治疗调节性 CD8 T 细胞
- 批准号:
9338988 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Immunotherapeutic Regulatory CD8 T cells in Autoimmune Demyelinating Disease
自身免疫性脱髓鞘疾病中的免疫治疗调节性 CD8 T 细胞
- 批准号:
10248844 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Immunotherapeutic Regulatory CD8 T cells in Autoimmune Demyelinating Disease
自身免疫性脱髓鞘疾病中的免疫治疗调节性 CD8 T 细胞
- 批准号:
10447061 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Immune Dysregulation During Multiple Sclerosis Relapse
多发性硬化症复发期间的免疫失调
- 批准号:
9929670 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Immune Dysregulation During Multiple Sclerosis Relapse
多发性硬化症复发期间的免疫失调
- 批准号:
9915848 - 财政年份:2016
- 资助金额:
-- - 项目类别:
CNS-Specific Regulatory CD8+ T Cells in Autoimmune Demyelination
CNS 特异性调节 CD8 T 细胞在自身免疫性脱髓鞘中的作用
- 批准号:
8627103 - 财政年份:2011
- 资助金额:
-- - 项目类别:
CNS-Specific Regulatory CD8+ T Cells in Autoimmune Demyelination
CNS 特异性调节 CD8 T 细胞在自身免疫性脱髓鞘中的作用
- 批准号:
8648996 - 财政年份:2011
- 资助金额:
-- - 项目类别:
相似海外基金
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
VLA-4™ 靶向 67Cu-LLP2A 预处理增强基于 T 细胞的过继免疫疗法的疗效
- 批准号:
10713034 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Phase I first-in-human trial for ThINKK adoptive immunotherapy in children with high-risk cancers
针对高危癌症儿童的ThINKK过继免疫疗法的I期首次人体试验
- 批准号:
484371 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Phase I first-in-human trial of ThINKK adoptive immunotherapy in children with high-risk cancers
针对高危癌症儿童的ThINKK过继免疫疗法的I期首次人体试验
- 批准号:
473376 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Operating Grants
Development of Adoptive Immunotherapy Focusing on Follicular Helper T Cell Biology
专注于滤泡辅助 T 细胞生物学的过继免疫疗法的发展
- 批准号:
21K16420 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
数学模型引导的膀胱癌过继免疫治疗
- 批准号:
10180117 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
数学模型引导的膀胱癌过继免疫治疗
- 批准号:
10364687 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
数学模型引导的膀胱癌过继免疫治疗
- 批准号:
10599851 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Development of a combinatorial approach of antibody therapeutics and adoptive immunotherapy for cancer
开发抗体疗法和癌症过继免疫疗法的组合方法
- 批准号:
21K19422 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Elucidation of the function of the new NK cell subset and its application to adoptive immunotherapy
阐明新NK细胞亚群的功能及其在过继性免疫治疗中的应用
- 批准号:
21H04832 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (A)
Adoptive immunotherapy for adult T-cell leukemia/lymphoma with ex vivo expanded multi-tumor associated antigen specific cytotoxic T-cells
使用离体扩增的多肿瘤相关抗原特异性细胞毒性 T 细胞对成人 T 细胞白血病/淋巴瘤进行过继免疫治疗
- 批准号:
20K17375 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




